Skip to contentL
Lexicon Pharmaceuticals, Inc.
L
LXRXLexicon Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$1.74M$1.74M+1,076.4% vs Q3 2023 Net Income-$64.81M-$64.81MN/M vs Q3 2023 EPS Diluted-$0.18-$0.18N/M vs Q3 2023 Operating Income-$63,693,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lexicon Pharmaceuticals, Inc. · CIK 1062822 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$53,926,000N/M Margins · derivedOperating margin-3658.4%+29876.0 pt vs Q3 2023
Net margin-3722.6%+30415.9 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 13, 2024 · 44 d after period end